and you, morning, good Gordon everyone. Thank
being forward IND dosing actively up Syndrome clinical clinical and to year. patients. running, Quoin conducted I'm later are this very Netherton providing Both a XXXX. recruiting We to of has very had which open and our look data are an under start to that report fully pleased trials, strong
outside deepen understanding as and territories key requirements, countries foundations for full of US with both to for make approval. in to progress they early in Europe the their access as advocacy authorities, regulatory opinion well their commercial partners leaders as respective entry and into continue XX engage of Our regulatory the programs
also are pricing is and approved, reimbursement providers reimbursement and will with established to criteria. once partners smooth Our insurance efficient ensure working commercial our occur that and with rollout product a experts
currently been are As know, various for a so the the treatments of are interactions is there commercial with agencies anywhere performed no by Netherton of advance first approved and you why world, approval. in Syndrome our providers insurance regulatory kind, work these partners has the which in
to of stage earlier Queensland continue programs the during QUT, Australia with Our quarter. in advance University Technology, or
at Netherton shareholder downstream potential and development earlier are an portfolio to components QRXXXX value. of important development have of programs stage than continue our for to generate believe the these they While Syndrome, that we are significant
expenses. the to million and completed raise During a $X fees of we prior quarter capital also, successfully
of raise I past of think our it majority that the that this is terms peer raise more were worth in companies favorable obtained this also than those noting a capital a completed quarter. group by
firepower as conducting previously strengthen additional reason sheet and broaden we we company the actively our M&A to product As provide pursue this rare balance to our portfolio skin for raise a opportunities have discussed, beyond primary diseases. with was
and particularly strengths. rare space competitive by identifiable in commercial the disease that are readily in highly late on are clinical orphan assets based We and strong interested underpinned opportunities data stage favorable
our to with path current evaluation commercial the considering rare criteria opportunity thereafter. actively the commercialization skin of of primary being focus therapeutic a the and scale the are We range beyond areas
throughout momentum of quarter. into potential challenging and M&A companies highly large environment proven this to maintained past This many has have a assess as quarter, quite result, has for a the and an that opportunity current we opportunities had be market to been number
across a important systematic a Our and due metrics. diligence M&A in and approach experience number team employ of we deep to has thorough
of Quoin. there and want guarantees several advanced transformational discussions key when you everyone that a our We updating a While be we I an M&A announcement I is very number tell will transaction exciting fundamentally but portfolio that to forward reiterate make, be could have if to can look this Quoin with are in product be regarding through can we including to that companies do some for priority potentially broadening a no for that year. consummated, opportunities,
QRXXXX different are note, frequently competitive in the we for questions Syndrome. On asked a about landscape Netherton
development a another and Netherton a as filed has an that proceed for the initiate Syndrome. with study company received of clinical IND aware are potential FDA product treatment We their to the may notification
want a do and between a to it is what has are been study. a potentially the stage by Xb itself their earlier testing ours. we product Principally Please in differences is as company as first much key a that our labeled study study. Phase currently part of registrational of recall a the number take their ours program highlight I moment at and than now clinical
In in XX addition, differs ongoing study true of according versus studies. endpoints publicly endpoints being of efficacy information, different for and weeks available in them clinical their to two clinical the than their both appear for assessed ours dosing somewhat to terms our duration, us, from weeks be
process other believe cost-effective Finally, our available on company. again, overlap the advantages of based configure significant and manufacturing publicly may well-defined we information, reproducible
company an remains appear of best does Syndrome the under open study has As company that in Netherton the only to trials now, the clinical clinical their conducting and knowledge, initiated not IND. our of it Quoin
us very manufacturing a first advantage, mover to approval regulatory on well-established this believe the obtain potential product process acknowledging with believe the treat track the to we a provides of presence advanced for space, we we clinical first are Syndrome. our and competitor stage substantial of a Whilst coupled with Netherton in cost-effective program
Europe, a established next in combination of that no countries similar global commercial in have commercial coupled essentially is the peer we previously, claim. our QRXXXX could other outlined those and enable once As know company XX with group a of will We plan to the Quoin affect launch of infrastructure what partnership territories make the network in US outside our approved.
Gordon With financial let operational discuss our over first that results. it to our to turn update quarter on progress, me
